Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. - Wikidata - awgldk - TriplyDB

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

http://www.wikidata.org/entity/Q43904283

about

Gender analysis of moxifloxacin clinical trials Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.Alternative and rescue treatment regimens for Helicobacter pylori eradication.Helicobacter pylori: the challenge in therapy.Review article: the treatment of refractory Helicobacter pylori infection.Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.Effective regimens for the treatment of Helicobacter pylori infection.Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis.Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems.Should quinolones come first in Helicobacter pylori therapy?Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate.Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.How effective is moxifloxacin for the first-line treatment of patients with Helicobacter pylori infection?Helicobacter pyloritherapy: what is coming?Evolving therapy for Helicobacter pylori infection

P2860

Q28538319-DD2E7360-2A58-4348-BA78-98500A65F07C Q33843119-3FFBDC8A-7EC0-47F7-83AE-1A34310AAC51 Q33844196-E870EE2F-6B1D-451A-9B83-9346DA3B5B89 Q34789141-2290571C-B5C3-4AD8-83D2-7A86D7C969A4 Q34799596-CD439C72-2472-4111-8D22-2861AC159153 Q35145092-7C3E4711-AD32-45F4-8E02-799B3EB1584C Q35594239-E2CD797E-91DF-430F-B8A0-27976BFA967F Q35771863-281A5242-23F4-4FFB-A72F-23B88836EFF4 Q35917226-8985F1F1-AEE3-4CF4-BB37-F9EFC9E6A802 Q36568724-263A8E00-8A0E-4B7C-A4CA-7E76849E9F1D Q37857355-524B087C-2B3C-473C-8C5C-B80482BAA14D Q38793537-F7AAF024-DD59-47FB-A761-DFDBA1275084 Q41807465-46CBE5AE-9675-4A0E-AFE4-C6EB7B76C8AE Q43708032-B6CE49EB-E762-49D7-8C8C-7328A11FE75A Q44700551-66060EAD-55BC-4FC4-9CB0-7417C0AC6144 Q45126233-5A845715-8CE8-4FE8-8F09-8C33F262EA36 Q46099612-CAC39AD4-E00B-49EA-803A-7B881E96F4B5 Q46480398-96E8B007-0B5E-4DA6-871E-95F96C03FBE2 Q46752417-A9E465F1-BFAC-4C0A-94EF-27A19EFEA839 Q57821526-AF65A261-EAE1-4D2F-B318-3A2C3A713C02 Q57821560-270E8E17-1CD4-46DD-AB0B-91C6782B9A2F

P2860

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

http://www.wikidata.org/entity/Q43904283

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@en

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@nl

type

label

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@en

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@nl

prefLabel

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@en

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@nl

P1433

Q43904283-A3CF8315-8D8E-4ED4-9F08-653F5A275CBD

P1476

Q43904283-D029A668-C744-4B69-AB41-3620EA297806

P2093

Q43904283-01FE8BBD-C82E-4A6D-A7BC-7120C2F77175

Q43904283-48F369DC-C1C2-4E1A-837D-4EEEB77AC611

Q43904283-56893762-BB05-4BD4-938E-D68B57E3E46D

Q43904283-5BB18C1A-C524-4798-A266-9D54C0E09669

Q43904283-64C0860D-1034-424C-9B18-F6E60C2CA55F

Q43904283-742FFF56-E6EC-4D0E-87D3-05C1294A2BBC

Q43904283-7A07E27F-611F-4E96-887F-A6916C71EB7A

Q43904283-9BFF1B3A-B3FD-4BEE-A36D-CD95A9C191FA

Q43904283-E2B139B6-E229-42DA-83BF-F876F26A3B4B

Q43904283-E5E228B4-01C3-40E6-89A9-D5EF23CEF857

P2860

Q43904283-0C90F2B9-9F2D-4331-952F-99247591EE73

Q43904283-158B506D-BC8F-4825-A838-96AB2AFE3613

Q43904283-1B6B673E-57DA-470A-8375-730213E72244

Q43904283-1DA98D35-F89C-4F41-A5B7-955CA6C9DCF9

Q43904283-251C367A-95D9-40C1-B273-247E730BC0FC

Q43904283-274B037A-785F-48C3-9AEB-3B2C385AC652

Q43904283-28EFF368-8652-40B4-9D45-3800F57C7084

Q43904283-4B189B77-EB9A-4340-AB67-1ECCF180E5FA

Q43904283-5C9375E6-2E4C-4D98-BD8F-C256264C839A

Q43904283-5D64FBD9-0B10-4730-82D5-CB520B45FF47

P304

Q43904283-8C3EDB24-A47E-445A-8A0A-91DE891ED450

P31

Q43904283-5515E1CD-F99C-4D76-A1D4-B3BEB84ECAB7

P356

Q43904283-0B76EF2E-D11E-41AB-B0F8-90B03EF7A632

P407

Q43904283-5F3E6301-1C62-44DE-805D-2926817BD3FC

P433

Q43904283-7E753E49-94A2-45CF-86A5-09389C4EB585

P478

Q43904283-CCDC73F2-9B49-4FC9-883B-A5FDB6B054AF

P577

Q43904283-A8BE490D-0C7A-4179-BEF8-C3121EE94867

P5875

Q43904283-91616684-C14D-48CE-92E6-261857AC6E55

P698

Q43904283-B0832F6A-B9E0-4357-B847-EA99FB3BF655

P921

Q43904283-7A38634A-9B69-464E-B9E3-D8964973A855

P356

J.1365-2036.2002.01165.X

P1433

Alimentary Pharmacology & Therapeutics

P1476

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

@en

P2093

Bartolozzi F

http://www.w3.org/2001/XMLSchema#string

Cammarota G

http://www.w3.org/2001/XMLSchema#string

Candelli M

http://www.w3.org/2001/XMLSchema#string

Cremonini F

http://www.w3.org/2001/XMLSchema#string

Di Caro S

http://www.w3.org/2001/XMLSchema#string

Gasbarrini A

http://www.w3.org/2001/XMLSchema#string

Lupascu A

http://www.w3.org/2001/XMLSchema#string

Nista EC

http://www.w3.org/2001/XMLSchema#string

Ojetti V

http://www.w3.org/2001/XMLSchema#string

Zocco MA

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse reactions to fluoroquinolones. an overview on mechanistic aspects

Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

Safety profile of Lansoprazole: the US clinical trial experience.

Extradigestive manifestations of Helicobacter pylori gastric infection

Treatment after failure: the problem of "non-responders".

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates.

Quinolone activity against anaerobes.

Effect of quinolones on intestinal ecology.

P304

527-532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2036.2002.01165.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11485441

http://www.w3.org/2001/XMLSchema#string

P698

11876707

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori